Procept Biorobotics (PRCT)

• Market cap: $3.05B
• 1 day: -4.14%
• 5 days: -5.30%
• 1 month: -7.35%
• 3 months: -24.58%
• 6 months: -41.98%
• Year to date: -35.09%
• 1 year: 1.89%
• 5 years: 28.71%
• 10 years: 28.71%
• Sector: Healthcare
• Industry: Medical Devices

About: PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.

Employees: 756

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

106% more first-time investments, than exits

New positions opened: 64 | Existing positions closed: 31

53% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 75

29% more call options, than puts

Call options by funds: $19.5M | Put options by funds: $15.1M

11% more funds holding

Funds holding: 247 [Q3] → 275 (+28) [Q4]

11% more capital invested

Capital invested by funds: $3.65B [Q3] → $4.05B (+$402M) [Q4]

4.93% more ownership

Funds ownership: 88.08% [Q3] → 93.01% (+4.93%) [Q4]

13% less funds holding in top 10

Funds holding in top 10: 8 [Q3] → 7 (-1) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $70 30% upside
• Avg. target: $83 54% upside
• High target: $95 76% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

B of A Securities Craig Bijou 60% 1-year accuracy 6 / 10 met price target	56% upside $84	Buy Maintained	25 Apr 2025
Truist Securities Richard Newitter 57% 1-year accuracy 29 / 51 met price target	30% upside $70	Buy Maintained	11 Apr 2025
Morgan Stanley Patrick Wood 50% 1-year accuracy 6 / 12 met price target	76% upside $95	Overweight Maintained	26 Feb 2025